Aptose Reports Results for the Fourth Quarter and Full Year 2023
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
Aptose closes previously announced public offering and private placement
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
Aptose Tuspetinib Data Featured in Oral Presentation
Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
Aptose Reports Results for the Third Quarter 2023 ¢ TUS/VEN Therapy Active in R/R VEN Failure AML Patients Guides Toward Accelerated Approval Path
Dr. Naval Daver from MD Anderson Cancer Center will present data from Aptose™s AML Drug Candidate Tuspetinib in an Oral Presentation at ASH 2023
Aptose Presents Latest Available Data on AML Drug Tuspetinib - 48% ORR with TUS/VEN in Heavily Pre-treated R/R AML Patients